Cart
sales@molnova.com
FGF22-IN-1
CAS No. 113143-13-8
FGF22-IN-1( —— )
Catalog No. M36498 CAS No. 113143-13-8
FGF22-IN-1 is a potential CD4 N-terminal immunoglobulin variable region-like domain (CD4 D1) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 101 | In Stock |
|
| 10MG | 163 | In Stock |
|
| 25MG | 312 | In Stock |
|
| 50MG | 500 | In Stock |
|
| 100MG | 712 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1442 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFGF22-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionFGF22-IN-1 is a potential CD4 N-terminal immunoglobulin variable region-like domain (CD4 D1) inhibitor.
-
DescriptionFGF22-IN-1 (compound c1) is a potent CD4 D1 inhibitor. FGF22-IN-1 can be used as immunosuppressive agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number113143-13-8
-
Formula Weight269.32
-
Molecular FormulaC14H11N3OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (371.31 mM; Ultrasonic )
-
SMILESO=C(NN=CC1=CNC=2C=CC=CC12)C=3SC=CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xiao H, et al. Potent inhibition of the CD4-dependent T cell response by J2, a novel nonpeptide organic ligand of CD4 D1. Mol Immunol. 2007 Feb;44(5):784-95.?
molnova catalog
related products
-
Rel-TREM2 agonist-2
rel-5-(4-Chloro-2-fluorophenyl)-2,3-dimethyl-7-[(2R,4S)-tetrahydro-2-(1-methyl-1H-pyrazol-4-yl)-2H-pyran-4-yl]pyrido[3,4-b] The EC50 value of pyrazine against TREM2 was ≤ 0.05 μM and the E.max value was > 250 μM.
-
G6PD activator AG1
G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 μΜ.
-
BPK-29 hydrochloride
BPK-29 hydrochloride is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein interactions by covalently modifying C274.
